REGENXBIO Inc.
RGNX
$9.66
$0.293.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 174.48M | 87.82M | 170.44M | 161.32M | 155.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 174.48M | 87.82M | 170.44M | 161.32M | 155.78M |
| Cost of Revenue | 252.91M | 260.49M | 248.60M | 239.76M | 244.75M |
| Gross Profit | -78.42M | -172.67M | -78.16M | -78.44M | -88.96M |
| SG&A Expenses | 85.56M | 83.82M | 82.86M | 75.53M | 74.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 167.00K | 200.00K | 179.00K | 958.00K | 930.00K |
| Total Operating Expenses | 338.63M | 344.51M | 331.64M | 316.25M | 320.38M |
| Operating Income | -164.15M | -256.69M | -161.20M | -154.93M | -164.60M |
| Income Before Tax | -196.43M | -290.01M | -193.88M | -177.92M | -175.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -196.43 | -290.01 | -193.88 | -177.92 | -175.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -196.43M | -290.01M | -193.88M | -177.92M | -175.57M |
| EBIT | -164.15M | -256.69M | -161.20M | -154.93M | -164.60M |
| EBITDA | -148.78M | -241.17M | -145.58M | -139.16M | -148.75M |
| EPS Basic | -3.78 | -5.59 | -3.75 | -3.46 | -3.44 |
| Normalized Basic EPS | -2.36 | -3.49 | -2.35 | -2.16 | -2.15 |
| EPS Diluted | -3.79 | -5.60 | -3.76 | -3.47 | -3.44 |
| Normalized Diluted EPS | -2.37 | -3.49 | -2.35 | -2.16 | -2.15 |
| Average Basic Shares Outstanding | 208.69M | 207.35M | 206.29M | 205.41M | 204.52M |
| Average Diluted Shares Outstanding | 208.89M | 207.35M | 206.36M | 205.48M | 204.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |